Champlain Investment Partners LLC Cuts Stake in Omnicell, Inc. (NASDAQ:OMCL)

Champlain Investment Partners LLC trimmed its position in Omnicell, Inc. (NASDAQ:OMCL) by 10.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,547,004 shares of the company’s stock after selling 176,821 shares during the period. Champlain Investment Partners LLC owned about 3.36% of Omnicell worth $67,449,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of OMCL. Nisa Investment Advisors LLC increased its position in shares of Omnicell by 248.8% during the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock worth $38,000 after purchasing an additional 1,000 shares in the last quarter. GAMMA Investing LLC boosted its stake in Omnicell by 78.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after purchasing an additional 553 shares during the last quarter. EntryPoint Capital LLC grew its holdings in shares of Omnicell by 121.2% during the first quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock worth $72,000 after buying an additional 1,345 shares in the last quarter. CWM LLC raised its position in shares of Omnicell by 68.2% in the second quarter. CWM LLC now owns 3,048 shares of the company’s stock valued at $83,000 after buying an additional 1,236 shares during the last quarter. Finally, 1620 Investment Advisors Inc. raised its position in shares of Omnicell by 230.1% in the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock valued at $96,000 after buying an additional 1,542 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. StockNews.com lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Craig Hallum boosted their target price on Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Benchmark reiterated a “buy” rating and set a $48.00 price objective on shares of Omnicell in a research report on Wednesday, October 9th. Bank of America reiterated a “neutral” rating and set a $57.00 price objective (up previously from $44.00) on shares of Omnicell in a research report on Thursday, October 31st. Finally, JPMorgan Chase & Co. raised their target price on Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research note on Thursday. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $52.00.

Omnicell Trading Up 3.6 %

Shares of Omnicell stock opened at $45.69 on Friday. The stock has a 50 day moving average of $44.22 and a 200 day moving average of $37.25. Omnicell, Inc. has a fifty-two week low of $25.12 and a fifty-two week high of $55.74.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.